ACP
CRBP icon

Altitude Crest Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Altitude Crest Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-103,703
Closed -$4.07M – 8
2024
Q1 		$4.07M Buy
+103,703
New +$2.56M 1.74% 20

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Altitude Crest Partners's CRBP Position: Q2 2024 in Review

Altitude Crest Partners sold out of Corbus Pharmaceuticals (CRBP) in Q2 2024, closing a stake of 103,703 shares — an estimated $4.07M sold.

Altitude Crest Partners first reported a position in CRBP in Q1 2024 and held it in 1 quarter. The position peaked at $4.07M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2024.

  • Altitude Crest Partners reported no remaining Corbus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 103,703 Corbus Pharmaceuticals shares in Q2 2024, an estimated $4.07M.
  • Altitude Crest Partners first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Corbus Pharmaceuticals position peaked at $4.07M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.